U.S. markets close in 6 hours 26 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.00+0.12 (+0.34%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close34.88
Open35.00
Bid17.03 x 1100
Ask0.00 x 900
Day's Range34.99 - 35.00
52 Week Range26.38 - 63.22
Volume20,651
Avg. Volume249,089
Market Cap1.576B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
    GlobeNewswire

    PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

    CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Napa Biopharma Virtual Conference on Monday, June 14th. Details on the presentation can be found below. Bank of America Securities 2021 Nap

  • PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
    GlobeNewswire

    PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference

    CRANBURY, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference on Wednesday, June 9, 2021. The company will also participate in one-on-one investor meetings at the conference. Details

  • PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
    GlobeNewswire

    PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

    Presented late breaking preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research Annual Meeting 2021Expanded Board of Directors with the appointment of Charles M. Baum, M.D., Ph.D.Appointed Guillermina (Gigi) Lozano, Ph.D. to the Scientific Advisory Board CRANBURY, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the quarter ended March 31, 2021 and provided corporate highlights. “PMV had a successful first quarter. We continued to advance our clinical and discovery programs, and our presentation at AACR provided compelling evidence that PC14586 selectively reactivates the p53 Y220C mutant protein, both in vitro and in vivo,” said David Mack, Ph.D., President and Chief Executive Officer. “Enrollment in our Phase 1/2 trial of PC14586, our first in class p53 Y220C reactivator, is progressing as planned. We are also thrilled to have welcomed Chuck Baum to our Board and Gigi Lozano to our SAB and look forward to leveraging their deep expertise in precision therapeutics and genetic drivers of cancer.” Corporate Highlights: In March 2021, PMV Pharma presented late breaking preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research Annual Meeting 2021. The Oral presentation titled, “PC14586: The First Orally Bioavailable Small Molecule Reactivator of Y220C Mutant p53 in Clinical Development” was given by Melissa L. Dumble, Ph.D., Vice President Preclinical Development and Translational Science of PMV.PMV Pharma continued to enroll patients in the Phase 1 portion of a Phase 1/2 clinical trial of PC14586 (NCT04585750). PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.Appointment of Charles Baum, M.D., Ph.D., to the Board of Directors. Dr. Baum is the President and Chief Executive Officer and a Board Member of Mirati Therapeutics Inc.Expanded Scientific Advisory Board with the appointment of p53 pioneer Dr. Guillermina (Gigi) Lozano, Professor and Chair, Department of Genetics, MD Anderson Cancer Center.PMV Pharma is the process of relocating to a state-of-the-art laboratory and office building located in Princeton, NJ. First Quarter 2021 Financial Results PMV Pharma ended the fourth quarter with $348.4 million in cash, cash equivalents, and marketable securities, compared to $361.4 million as of December 31, 2020. Net cash used in operations was $12.9 million for the three months ended March 31, 2021 compared to $8.1 million for the three months ended March 31, 2020.Net loss for the quarter ended March 31, 2021 was $11.6 million compared to $7.3 million for the quarter ended March 31, 2020.Research and development (R&D) expenses were $7.5 million for the three months ended March 31, 2021 compared to $6.0 million for the three months ended March 31, 2020. The increase in R&D expenses was primarily related to increased headcount and clinical expenses for advancing development of PC14586, the Company’s lead drug candidate.General and administrative (G&A) expenses were $4.2 million for the three months ended March 31, 2021, compared to $1.7 million for the three months ended March 31, 2020. The increase in G&A expenses was primarily due to expanding the infrastructure necessary for operating as a public company. About p53 p53 plays a pivotal role in preventing abnormal cells from becoming a tumor by inducing programmed cell death. Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy. The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian cancers. About PC14586 PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the crevice present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein structure and tumor suppressing function. PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have the p53 Y220C mutation and has been granted Fast Track designation by the U.S. FDA. About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for PC14586, including expectations regarding the timing for patient enrollment and success of its current clinical trial for PC14586; the future plans or expectations for the Company’s discovery platform; and the period over which the Company estimates its existing cash and cash equivalents will be sufficient to fund its current operating plan. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities and planned clinical trials, the Company’s ability to execute on its strategy and operate as an early clinical stage company, the potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2021, the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2021 and its other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. PMV Pharmaceuticals, Inc.Consolidated Balance Sheet Data(unaudited, in thousands) March 31,2021(unaudited) December 31,2020 Assets Current assets: Cash and cash equivalents $208,783 $361,422 Marketable securities, current 122,706 — Prepaid expenses and other current assets 3,464 3,339 Total current assets 334,953 364,761 Property and equipment, net 697 569 Marketable securities, noncurrent 16,891 — Right-of-use assets, operating leases 828 — Other assets 1,024 201 Total assets $354,393 $365,531 Liabilities, Convertible Preferred Stock, and Stockholders’ Equity Current liabilities: Accounts payable $1,252 $1,607 Accrued expenses 3,878 4,803 Operating lease liability, current 666 — Total current liabilities 5,796 6,410 Operating lease liability, noncurrent 302 — Total liabilities 6,098 6,410 Stockholders’ equity: Common stock — — Additional paid-in capital 469,790 469,001 Accumulated deficit (121,482) (109,880)Accumulated other comprehensive loss (13) — Total stockholders’ equity 348,295 359,121 Total liabilities and stockholders’ equity $354,393 $365,531 PMV Pharmaceuticals, Inc.Statements of Operations and Comprehensive Loss(unaudited, in thousands, except share and per share amounts) Three Months Ended March 31, 2021 2020 Operating expenses: Research and development $7,500 $5,955 General and administrative 4,174 1,699 Total operating expenses 11,674 7,654 Loss from operations (11,674) (7,654)Other income (expense): Interest income, net 128 406 Other expense (52) (5)Total other income 76 401 Loss before provision for income taxes (11,598) (7,253)Provision for income taxes 4 2 Net loss (11,602) (7,255)Unrealized gains (losses) on marketable securities, net of tax (13) (80)Comprehensive loss $(11,615) $(7,335)Net loss per share -- basic and diluted $(0.26) $(2.38)Weighted-average common shares outstanding 44,785,226 3,046,200 Contact For Investors & Media: Winston KungChief Financial Officerinvestors@pmvpharma.com